neoadjuvant chemo-immunotherapy-Sun Yat-sen University-non-small cell lung cancer

This entry refers to a specific neoadjuvant treatment regimen evaluated in a Phase II clinical trial sponsored by Sun Yat-sen University for patients with locally advanced non-small cell lung cancer (NSCLC). The regimen consists of chemo-immunotherapy, specifically the PD-1 inhibitor tislelizumab combined with standard chemotherapy, with or without the addition of the anti-VEGF antibody bevacizumab. This neoadjuvant phase is designed to reduce tumor burden and potentially eradicate micrometastases before patients proceed to definitive concurrent chemoradiation therapy and subsequent consolidation therapy with tislelizumab. Tislelizumab is a humanized IgG4 monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby restoring T-cell mediated anti-tumor immune responses. The chemotherapy component typically involves platinum-based agents that induce DNA damage and cell death.

Other names

neoadjuvant chemo-immunotherapyTislelizumab plus chemotherapyTislelizumab plus chemotherapy plus bevacizumab